sterna biologicals announces data with gata-3 specific dnazyme SB012 to be presented at Digestive Disease Week®
Marburg, Germany, May 29, 2018
- Further insights and data from Phase 2a trial in ulcerative colitis
Sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that further insights and data from a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its DNAzyme candidate SB012 will be presented at Digestive Disease Week® (DDW) in Washington, DC, June 2-5, 2018.